Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Aprea Therapeutics Inc has a consensus price target of $10.6 based on the ratings of 5 analysts. The high is $20 issued by HC Wainwright & Co. on August 12, 2024. The low is $2 issued by HC Wainwright & Co. on March 16, 2022. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and HC Wainwright & Co. on August 13, 2024, August 12, 2024, and June 24, 2024, respectively. With an average price target of $17 between Wedbush, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 443.13% upside for Aprea Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Aprea Therapeutics (NASDAQ:APRE) was reported by Wedbush on August 13, 2024. The analyst firm set a price target for $11.00 expecting APRE to rise to within 12 months (a possible 251.44% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Aprea Therapeutics (NASDAQ:APRE) was provided by Wedbush, and Aprea Therapeutics reiterated their outperform rating.
There is no last upgrade for Aprea Therapeutics
There is no last downgrade for Aprea Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aprea Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aprea Therapeutics was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.
While ratings are subjective and will change, the latest Aprea Therapeutics (APRE) rating was a reiterated with a price target of $11.00 to $11.00. The current price Aprea Therapeutics (APRE) is trading at is $3.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.